Information Transparency in the Drug Approval Process.
Publication
, Journal Article
Rini, BI; Burstein, HJ; George, DJ
Published in: JAMA Oncol
November 1, 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
November 1, 2018
Volume
4
Issue
11
Start / End Page
1621 / 1622
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- Sunitinib
- Kidney Neoplasms
- Humans
- Drug Approval
- Carcinoma, Renal Cell
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Rini, B. I., Burstein, H. J., & George, D. J. (2018). Information Transparency in the Drug Approval Process. JAMA Oncol, 4(11), 1621–1622. https://doi.org/10.1001/jamaoncol.2018.4143
Rini, Brian I., Harold J. Burstein, and Daniel J. George. “Information Transparency in the Drug Approval Process.” JAMA Oncol 4, no. 11 (November 1, 2018): 1621–22. https://doi.org/10.1001/jamaoncol.2018.4143.
Rini BI, Burstein HJ, George DJ. Information Transparency in the Drug Approval Process. JAMA Oncol. 2018 Nov 1;4(11):1621–2.
Rini, Brian I., et al. “Information Transparency in the Drug Approval Process.” JAMA Oncol, vol. 4, no. 11, Nov. 2018, pp. 1621–22. Pubmed, doi:10.1001/jamaoncol.2018.4143.
Rini BI, Burstein HJ, George DJ. Information Transparency in the Drug Approval Process. JAMA Oncol. 2018 Nov 1;4(11):1621–1622.
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
November 1, 2018
Volume
4
Issue
11
Start / End Page
1621 / 1622
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- Sunitinib
- Kidney Neoplasms
- Humans
- Drug Approval
- Carcinoma, Renal Cell
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis